Immunocore Holdings plc - ADR
IMCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.73B
Close$
$-21.06
161.6% downside
Current Fair Value
161.6% downsideOvervalued by 161.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.73 Billion |
|---|---|
| Enterprise Value | $1.68 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.73 |
| Outstanding Shares | 50,973,830 |
Return
| Return on Equity | -2.22% |
|---|---|
| Return on Assets | -0.83% |
| Return on Invested Capital | -0.78% |
Valuation & Multiples
| P/E Ratio | -184.38 |
|---|---|
| PEG | 200.08 |
| Price to Sales | 4.89 |
| Price to Book Ratio | 4.28 |
| Enterprise Value to Revenue | 4.16 |
| Enterprise Value to EBIT | -241.88 |
| Enterprise Value to Net Income | -180 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 1.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$148.57 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$152.58 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0000▼ 764.83% |
|---|---|
| Total Calls | 30,000▼ 84.23% |
| Total Puts | 30,000▼ 98.18% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.29%▼ 97.94% |
|---|---|
| Total Invested | $85.30M▼ 94.60% |
| Investors Holding | 39▼ 114.00% |
ESG Score
No data
About Immunocore Holdings plc
2,020 employeesImmunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of disea...